International Biotechnology Trust’s Relmada Therapeutics RLMD Stock Holding History

International Biotechnology Trust’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$30K	Hold	10,000	–	–	0.01%	65
2023 Q2	$24.7K	Hold	10,000	–	–	0.01%	61
2023 Q1	$22.5K	Hold	10,000	–	–	0.01%	64
2022 Q4	$34.9K	Hold	10,000	–	–	0.01%	63
2022 Q3	$370K	Buy	10,000 +9,810	+5,163%	+$272K	0.12%	62
2022 Q2	$10K	Sell	190 -9,810	-98%	-$214K	0.1%	75
2022 Q1	$741K	Hold	10,000	–	–	0.17%	61
2021 Q4	$225K	Hold	10,000	–	–	0.05%	71
2021 Q3	$261K	Buy	+10,000	New	+$268K	0.06%	65

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

International Biotechnology Trust's RLMD Position: Q3 2023 in Review

International Biotechnology Trust held its Relmada Therapeutics (RLMD) position steady in Q3 2023 at 10,000 shares worth $30K. The position accounts for 0.01% of the portfolio, ranked #65.

International Biotechnology Trust first reported a position in RLMD in Q3 2021 and has held it in 9 quarters since. The position peaked at $741K in Q1 2022. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2023.

International Biotechnology Trust held 10,000 shares of Relmada Therapeutics worth $30K as of Q3 2023.
International Biotechnology Trust left its Relmada Therapeutics share count unchanged in Q3 2023.
Relmada Therapeutics made up 0.01% of International Biotechnology Trust's portfolio in Q3 2023, its #65 holding.
International Biotechnology Trust first reported a position in Relmada Therapeutics in Q3 2021 and has held it in 9 quarters since.
International Biotechnology Trust's Relmada Therapeutics position peaked at $741K in Q1 2022.
87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.